Mads Harsløf

Mads Harsløf serves as a Guest Researcher at the Grønbæk Group within the Biotech Research and Innovation Centre (BRIC) at the University of Copenhagen, Denmark, located at Ole Maaløes Vej 5, 2200 Copenhagen N. His research focuses on translational hematology and oncology, with primary institutional affiliation under Professor Kirsten Grønbæk's team specializing in blood cancer research.

Harsløf's research interests center on Hematology and Oncology, with significant contributions to understanding multiple myeloma, B-cell lymphoma, and infectious disease interactions in cancer patients. His work spans Clinical Research methodologies, Epidemiological cohort studies, and earlier Neuroscience imaging techniques. Key investigations include bispecific antibody therapies for lymphoma, genetic alterations in myeloma progression, real-world implementation of maintenance treatments, and lipid metabolism's role in infectious outcomes. This multidisciplinary approach bridges laboratory findings with clinical applications in hematologic malignancies.

Analysis of his 2023-2024 publications reveals a concentrated trend in hematologic malignancy research, particularly examining novel immunotherapies' safety profiles during infectious outbreaks like COVID-19 and evaluating real-world efficacy of maintenance regimens in multiple myeloma. His studies frequently employ large-scale population data and collaborative clinical frameworks, demonstrating methodological rigor in translational oncology while maintaining earlier neuroscience expertise.

No scientific awards or honors were documented in the available information.

No details regarding student advising responsibilities or research grant acquisitions were provided in the source material.

Harsløf operates within the Grønbæk Group at BRIC, a leading translational research unit focused on molecular mechanisms of blood cancers and therapeutic innovation. The group maintains strong clinical connections with Copenhagen University Hospital and international hematology networks, facilitating rapid translation of laboratory discoveries into patient care protocols for hematologic malignancies.